Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Income from Continuing Operations (2020 - 2022)

Atea Pharmaceuticals has reported Income from Continuing Operations over the past 3 years, most recently at 34431000.0 for Q4 2022.

  • Quarterly results put Income from Continuing Operations at 34431000.0 for Q4 2022, down 129.4% from a year ago — trailing twelve months through Dec 2022 was 115909000.0 (down 195.64% YoY), and the annual figure for FY2025 was 158349000.0, up 5.96%.
  • Income from Continuing Operations for Q4 2022 was 34431000.0 at Atea Pharmaceuticals, down from 8066000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for AVIR hit a ceiling of 117132000.0 in Q4 2021 and a floor of 42077000.0 in Q1 2022.
  • Median Income from Continuing Operations over the past 3 years was 9029500.0 (2020), compared with a mean of 472166.67.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 870.14% in 2021 and later plummeted 2136.06% in 2022.
  • Atea Pharmaceuticals' Income from Continuing Operations stood at 20656000.0 in 2020, then skyrocketed by 467.06% to 117132000.0 in 2021, then tumbled by 129.4% to 34431000.0 in 2022.
  • The last three reported values for Income from Continuing Operations were 34431000.0 (Q4 2022), 8066000.0 (Q3 2022), and 31335000.0 (Q2 2022) per Business Quant data.